Opportunity ID: 90413

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-11-NFRP-IIRA
Funding Opportunity Title: DoD Neurofibromatosis Investigator-Initiated Research Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 2
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 28, 2011
Last Updated Date:
Original Closing Date for Applications: Aug 01, 2011
Current Closing Date for Applications: Aug 01, 2011
Archive Date: Aug 31, 2011
Estimated Total Program Funding: $2,100,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The NFRP Investigator-Initiated Research Award mechanism was first offered in FY96. Since then, 341 Investigator-Initiated Research Award applications have been received, and 96 have been recommended for funding.
The NFRP Investigator-Initiated Research Award supports basic and clinically oriented research that will:
� Provide insight into the development of NF and Schwannomatosis,
� Result in substantial improvements over today�s approach to the diagnosis and treatment of NF and/or Schwannomatosis, and
� Have an impact on the quality of life of persons with those diseases.
DOD FY11 NFRP Investigator-Initiated Research Award 4
Areas of Encouragement: The FY11 NFRP encourages research applications that specifically address the critical needs of the NF community in the following areas:
� Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities;
� Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
� Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and
� Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF.
Applications must include preliminary data that is relevant to NF and/or Schwannomatosis and the proposed project.
Optional Qualified Collaborator: The FY11 NFRP strongly supports collaborative research between basic scientists and clinical researchers, and between academic scientists and biotechnology/pharmaceutical industry scientists. Collaborations that bring new perspectives from other disciplines, or bring new investigators into the NF field are also strongly encouraged.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

PA HELP: 301-682-5507; help@cdmrp.org

eReceipt HELP: 301-682-5507; help@cdmrp.org

Email:help@cdmrp.org

Version History

Version Modification Description Updated Date

Folder 90413 Full Announcement-1 -> fy11_nfrp iira pa_gg.pdf

Packages

Agency Contact Information: PA HELP: 301-682-5507; help@cdmrp.org
eReceipt HELP: 301-682-5507; help@cdmrp.org

Email: help@cdmrp.org

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00050610 Apr 28, 2011 Aug 01, 2011 View

Package 1

Mandatory forms

90413 RR_SF424_1_2-1.2.pdf

90413 PerformanceSite_1_4-1.4.pdf

90413 RR_Budget-1.1.pdf

90413 RR_KeyPersonExpanded_1_2-1.2.pdf

Optional forms

90413 RR_SubawardBudget30-1.2.pdf

2025-07-13T03:34:00-05:00

Share This Post, Choose Your Platform!

About the Author: